

Original Article

Euscaphic acid inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway

Weibo Dai^{1*}, Pengpeng Dong^{2*}, Jing Liu³, Yuqiao Gao¹, Ying Hu¹, Hui Lin¹, Ye Song¹, Quanxi Mei¹

¹Pharmacology Laboratory, Zhongshan Hospital, Guangzhou University of Chinese Medicine, Zhongshan 528401, Republic of China; ²Department of New Drug Analysis, New Drug Institute, Sunshine Lake Pharma Co., Ltd, Dongguan 523871, Republic of China; ³Department of Biomedicine, Zhongshan Torch Polytechnic, Zhongshan 528436, Republic of China. *Equal contributors.

Received December 28, 2018; Accepted January 23, 2019; Epub April 15, 2019; Published April 30, 2019

Abstract: *Rubus alceaefolius* Poir. has been used for the treatment of nasopharyngeal carcinoma (NPC) in China for many years. Euscaphic acid is an active component of *Rubus alceaefolius* Poir. However, the mechanism of action of euscaphic acid in NPC remains unclear. In this study, Euscaphic acid inhibited the proliferation of NPC cells, induced apoptosis, and led to cell cycle arrest in the G1/S phase. In addition, euscaphic acid inhibited the expression of phosphatidylinositol 3-kinases (PI3K), phosphorylated protein kinase B (p-AKT), and phosphorylated mammalian target of rapamycin (p-mTOR) in NPC cells. The activation of the PI3K/AKT/mTOR signaling pathway by IGF-1 promoted cell proliferation, inhibited apoptosis, and cell cycle arrest in NPC cells. In conclusion, we demonstrated that euscaphic acid reduced cell proliferation and induced apoptosis and cell cycle arrest in NPC cells by suppressing the PI3K/AKT/mTOR signaling pathway.

Keywords: Euscaphic acid, nasopharyngeal carcinoma, PI3K, AKT, mTOR

Introduction

Nasopharyngeal carcinoma (NPC) is an uncommon disease in most countries, with an age-adjusted incidence for both sexes of less than one person per population of 100,000 [1]. However, the disease much more frequently in southern China, northern Africa, and Alaska. The people living in the province of Guangdong are especially prone to the disease [2]. Chemotherapy and radiotherapy are still the most common therapies for NPC: radiotherapy is the main treatment, but the 5-year survival rate is only approximately 50% [3]; and chemotherapy still has an important role in treatment, especially in advanced cases. However, these therapies may lead to side-effects [4, 5]. Therefore, it is necessary to look for more effective and less toxic drugs for NPC.

Traditional Chinese medicines (TCMs) have a long history of use for cancer treatment in China. In recent years, their use has become more accepted worldwide and the body of evi-

dence supporting the anticancer effect of TCMs increased [6-9]. Previous studies have reported demonstrating the anticancer effects of celastrol, oridonin, and cinnamic acid through the promotion of apoptosis and the inhibition of proliferation of NPC cells [10-12]. *Rubus alceaefolius* Poir. is a traditional Chinese medicine compound found in Jiangsu, Fujian, Taiwan, Guangdong, and the Guangxi Province. It has a wide range of pharmacological activities, including antibiotic [13, 14], anti-inflammatory [15], antitumor [16, 17], hepatoprotective [18, 19] effects. Traditionally, it is used in the treatment of NPC in southern China [20]. Euscaphic acid is a triterpene from the root of the *R. alceaefolius* Poir. It has been shown that euscaphic acid has DNA polymerase inhibitory activity and inhibits cell growth [21]. However, the role and mechanism of euscaphic acid against NPC remain unclear.

The PI3K/AKT/mTOR pathway is an important intracellular signal transduction pathway. It has already been reported to be related to cell activ-

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 1. Euscaphic acid inhibited the proliferation of CNE-1 and C666-1 cells. A. The chemical structural formula of Euscaphic acid. B. CNE-1, C666-1, and NP69 cells were analyzed in the CCK8 assay after exposure to different concentrations of euscaphic acid. C. NP69 cells, CNE-1 cells, and C666-1 cells were analyzed in the CCK8 assay after treatment with euscaphic acid for 24, 48, and 72 hours. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ vs 0 µg/ml group.

ities such as proliferation, migration, and invasion [22-24]. Signaling through the PI3K/AKT/mTOR pathway can be initiated by several mechanisms, all of which increase the activation of the pathway in cancer cells. We aimed to identify the relationship between euscaphic acid and the PI3K/AKT/mTOR signaling pathway.

In this study, we investigated the effects of euscaphic acid on the proliferation, cell cycle, and apoptosis of NPC cells. Subsequently, we analyzed the potential regulatory mechanism of the PI3K/AKT/mTOR signaling pathway in NPC cells.

Materials and methods

Cell cultures and drugs treatment

NP69 (non-transformed nasopharyngeal epithelial cells derived from the human nasopharynx), C666-1, and CNE-1 human NPC cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The three cell lines were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin and 100 µg/ml streptomycin (GIBCO BRL, New York, USA). All NPC cells were cultured at 37°C in a

humidified incubator with atmosphere containing 5% CO₂. Euscaphic acid was purchased from PUSH BIO-TECHNOLOGY (<http://www.push-herbchem.com/>), C₃₀H₄₈O₅, Chengdu, Sichuan, China; Chemical structural formula was showed in **Figure 1B**) and was dissolved in absolute ethanol. A euscaphic acid stock solution (1 mg/mL) was prepared with a final ethanol concentration of ≤2% and sterilized by passing through a membrane filter with a pore size of 0.22 µm.

Proliferation assays

Cell Counting Kit-8 (CCK-8; Beyotime, Shanghai, China) was used to evaluate the growth of CNE-1, C666-1, and NP69 cells were incubated with different concentrations of euscaphic acid (0, 5, 10, 15, 20, 25, 30, 35, and 40 µg/mL) in accordance with the manufacturer's instructions. CNE-1, C666-1, and NP69 cells (4×10³ cells/well) were seeded into 96-well plates in a final volume of 100 µL medium and cultured for 24, 48, or 72 h. At the end of the incubation period, CCK-8 solution (10 µL) was added to each well, mixed gently, and incubated for 4 h at 37°C. Subsequently, the optical density at 450 nm was measured by using a microplate reader. The survival rate of the non-treatment cells (0 µg/ml Euscaphic acid) was defined as

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 2. Euscaphic acid (0, 5, and 10 µg/mL) induces apoptosis and cell cycle arrest in CNE-1 and C666-1 cells. A. The effect of euscaphic acid on the cell cycle of CNE-1 and C666-1 cells was detected by flow cytometry. B. The effect of euscaphic acid on apoptosis in CNE-1 and C666-1 cells was detected by flow cytometry. *** $P < 0.001$.

100%, and the survival rate of cells from all other concentrations of Euscaphic acid was calculated separately from that of the control group. All assays were performed in triplicate.

Cell cycle analysis

The cell cycle was detected by using flow cytometry. Briefly, the cells were treated with euscaphic acid at various concentrations (0, 5, and 10 µg/mL) for 48 h, and then harvested, washed twice with 1× PBS, and re-suspended in 200 µL 1× PBS. The cells were fixed in 4 mL ice-cold 75% ethanol at 4°C overnight and stained with 200 µL propidium iodide (50 µg/

mL, Sigma-Aldrich), 20 µL RNase (1 mg/mL, Sigma-Aldrich) was added, and the cells were incubated in a 37°C water bath for 15-20 min to remove RNA. The cells were then analyzed by using a flow cytometer (Cytomics FC 500 MPL, Beckman Coulter). All assays were performed in triplicate.

Apoptosis assays

The cells were incubated with euscaphic acid at different concentrations (0, 5, and 10 µg/mL) for 48 h and assayed to determine the degree of induction of apoptosis. After incubation, the cells were harvested and washed twice with

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 3. Western blotting of apoptosis-associated and cell cycle-associated proteins after euscaphic acid treatment.




Figure 4. Western blotting of PI3K, p-AKT, AKT, p-mTOR, and mTOR after euscaphic acid treatment.

cold $1\times$ PBS, after which 1×10^5 cells/mL were re-suspended in 200 μ L binding buffer, stained with 5 μ L Annexin-V and PI (BD Biosciences) for 15 min in the dark at 25°C, and analyzed by using a flow cytometer (Cytomics FC 500 MPL, Beckman Coulter).

Western blotting

Total cellular protein was extracted by using pre-chilled RIPA buffer (Beyotime) containing protease inhibitors. Equal amounts of protein

samples were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Non-specific binding to the membrane was blocked by incubation in PBS with 0.1% Tween-20 (PBST) containing 5% non-fat milk at 25°C for 2 h. For the protein analysis, the membrane was incubated with the corresponding primary antibody overnight at 4°C, washed with PBST, and then incubated with the secondary the horseradish peroxidase (HRP)-conjugated antibody (1:10,000) at 25°C for 2 h. The membranes were rinsed and the protein bands were visualized by the application of enhanced chemiluminescence reagent (ThermoScientific). GAPDH was used as the loading control. The sections were incubated with the primary antibodies (anti-human phosphorylated PI3K (p-PI3K) polyclonal antibody (1:10,000; Santa Cruz), anti-human total PI3K (t-PI3K) polyclonal antibody (1:4,000; Santa Cruz), anti-human phosphorylated AKT (p-AKT) polyclonal antibody (1:10,000; Santa Cruz), anti-human total AKT (t-AKT) polyclonal antibody (1:4,000; Santa Cruz), anti-human mTOR polyclonal antibody (1:5,000; Santa Cruz), and anti-human GAPDH polyclonal antibody (1:1,0000; Abcam), respectively.

Statistical analysis

The SPSS 19.0 software package (IBM, Chicago, IL, USA) was used to calculate statistical analyses. All data were presented as the mean \pm SD, and Student's t-test or one-way analysis of variance (ANOVA) was used to compare the difference between two or more groups. *P* values of <0.05 were considered statistically significant. Graphs were created by using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). IC50 was calculated using GraphPad Prism 7.

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 5. Activation of the PI3K/AKT/mTOR pathway by IGF-1. The effect of euscaphic acid treatment supplemented with IGF-1 on the expression of PI3K, p-AKT/AKT, and p-mTOR/mTOR in CNE-1 and C666-1 cells as measured by western blotting.




Figure 6. Activation of the PI3K/AKT/mTOR pathway reversed the effect of euscaphic acid on cell proliferation. The effect of euscaphic acid supplemented with IGF-1 on the ability of cell proliferation in CNE-1 and C666-1 cells that were detected by CCK8 analysis. ** $P < 0.01$, *** $P < 0.001$.

Results

Euscaphic acid inhibited the proliferation of CNE-1 and C666-1 cells

CNE-1, C666-1, and NP69 cells were treated with euscaphic acid (0, 5, 10, 15, 20, 25, 30, 35, 40 $\mu\text{g}/\text{mL}$) for 48 h, and cell viability was determined using the CCK8 assay (**Figure 1A**). The CCK8 assay showed that proliferation was significantly suppressed by an increase in the concentration of euscaphic acid in both CNE-1 and C666-1 cells compared to that in NP69 cells. Additionally, result showed that for C666-1 and CNE-1 cells, the Euscaphic acid concen-

tration to reduce cell viability to 50% was about 36.86 $\mu\text{g}/\text{mL}$ ($\text{IC}_{50}=36.86$) and 33.39 $\mu\text{g}/\text{mL}$ ($\text{IC}_{50}=33.39$), respectively. We chose 0, 5, and 10 $\mu\text{g}/\text{mL}$ euscaphic acid for the subsequent study as these concentrations exerted only low cytotoxicity against the cells, thereby excluding the anti-proliferation effect of high-dose euscaphic acid in cancer cells. To investigate whether euscaphic acid inhibited the proliferation of CNE-1, C666-1, and NP69 cells, the CCK8 assay was performed significantly indicated that proliferation was inhibited in CNE-1 and C666-1 cells arrest in a dose- and time-dependent manner, but not in NP69 cells (**Figure 1B-D**).

Euscaphic acid induces apoptosis and cell cycle arrest in CNE-1 and C666-1 cells

To investigate the effect of euscaphic acid on the induction of apoptosis and cell cycle arrest in CNE-1 and C666-1 cells, flow cytometric analysis was used after treatment with different concentrations of euscaphic acid (0, 5, and 10 $\mu\text{g}/\text{mL}$). At 0 $\mu\text{g}/\text{mL}$, no effects on the cell cycle of NPC cells were observed. At 5 or 10 $\mu\text{g}/\text{mL}$, the proportion of cell cycle

arrest in the G1/S phase was altered (**Figure 2A**). In addition, the results indicated that an increase in euscaphic acid promoted the induction of apoptosis in CNE-1 cells (**Figure 2B**). The proportion of apoptotic cells increased with an increase in euscaphic acid concentration. Similar results were found in the C666-1 cells. The results confirmed that euscaphic acid significantly promoted apoptosis and inhibited the progression of the cell cycle in CNE-1 and C666-1 cells in a dose-dependent manner. Apoptotic and cell cycle-associated proteins were measured by western blotting. The results clearly illustrated that Bax, caspase-3, p21, and p27 were increased, whereas Bcl-2 and cyclin D1

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 7. Activation of the PI3K/AKT/mTOR pathway reversed the effect of euscaphic acid on cell cycle and apoptosis. A. The effect of euscaphic acid supplemented with IGF-1 on the cell cycle arrest of CNE-1 and C666-1 cells as detected by flow cytometry. B. The effect of euscaphic acid supplemented with IGF-1 on apoptosis in CNE-1 and C666-1 cells was detected by flow cytometry. *** $P < 0.001$.

were decreased after euscaphic acid treatment (Figure 3).

Euscaphic acid inhibited the PI3K/AKT/mTOR signaling pathway

The PI3K/AKT/mTOR pathway is an important signaling pathway for the regulation of cell pro-

liferation and the induction of apoptosis in cancer cells. To determine the effects of euscaphic acid, we detected the proteins in this pathway after treatment of cells with different concentrations of euscaphic acid (0, 5, and 10 $\mu\text{g}/\text{mL}$) by western blotting. As shown in Figure 4, euscaphic acid clearly suppressed the protein expression of PI3K, p-AKT/AKT, and p-mTOR/

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma




Figure 8. Effect of euscaphic acid supplemented with IGF-1 on the expression of apoptosis-associated and cell cycle regulatory proteins in CNE-1 and C666-1 cells as measured by western blotting after activation of the PI3K/AKT/mTOR pathway.

mTOR in a dose-dependent manner in CNE-1 and C666-1 cells. Euscaphic acid inhibited the NPC through the PI3K/AKT/mTOR signaling pathways. The expression of the components of the PI3K/AKT/mTOR pathways in both CNE-1 and C666-1 cell lines was detected by western blotting after treatment with different concentrations of euscaphic acid (0, 5, and 10 µg/mL).

Activation of the PI3K/AKT/mTOR pathway to reverse the effect of euscaphic acid

To confirm if euscaphic acid induced apoptosis and cell cycle arrest in CNE-1 and C666-1 cells through the suppression of the PI3K/AKT/mTOR signaling pathway, we further assessed whether the activation of the PI3K/AKT/mTOR signaling pathway by insulin-like growth factors-1 (IGF-1), a PI3K/AKT/mTOR signaling pathway activating agent, could reverse the effects of euscaphic acid in CNE-1 and C666-1 cells. First, we measured the expression of PI3K, p-AKT/AKT, and p-mTOR/mTOR in CNE-1 and C666-1 cells after treatment with euscaphic acid (10 µg/mL) and when supplemented with

IGF-1 or PBS. The results clearly showed that supplementation with IGF-1 increased the expression of PI3K, p-AKT/AKT, and p-mTOR/mTOR in CNE-1 and C666-1 cells compared to that when supplemented with PBS (**Figure 5**). The CCK8 assay suggested that supplementation with IGF-1 significantly promoted cell proliferation in both CNE-1 and C666-1 cells compared to that when supplemented with PBS (**Figure 6**). The flow cytometry assay indicated that supplementation with IGF-1 significantly promoted cell cycle progression and inhibited cell apoptosis both in CNE-1 and C666-1 cells (**Figure 7**). The results of the western blot analysis clearly showed that the expression of Bcl-2 and Cyclin D1 in the cells supplemented with IGF-1 was significantly increased, whereas the expression of Bax, caspase-3, p21, and p27 was decreased,

compared to that in cells supplemented with PBS (**Figure 8**).

Discussion

The antitumor activity of euscaphic acid has been previously reported. Banno *et al.* [25] confirmed the inhibitory effect of euscaphic acid on *in vivo* two-stage mouse skin carcinogenesis. Kim *et al.* [26] reported that tumor cells treated with different concentrations of euscaphic acid exhibited a significant decrease in proliferation in a dose-dependent manner. Rocha *et al.* [27] confirmed the antitumor activity of euscaphic acid in different types of cancer and showed that it induced apoptosis in a caspase-dependent manner. Nonetheless, there has been little research on the effects of euscaphic acid on NPC. In this study, we found that euscaphic acid inhibited the proliferation of CNE-1 and C666-1 cells, and induced apoptosis and cell cycle arrest, unlike in NP69 cells, in a dose- and time-dependent manner. We also found that euscaphic acid treatment clearly increased the expression of Bax, caspase-3, p21, and p27,

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma

whereas the expression of Bcl-2 and cyclin D1 was reduced. The results suggested that euscaphic acid exerts anticancer effects through the inhibition of proliferation and the induction of apoptosis in NPC.

Subsequently, we analyzed the antitumor effects of euscaphic acid in the NPC cells through the changes in the expression of PI3K, p-AKT, and p-mTOR to evaluate changes in the PI3K/AKT/mTOR signaling pathway. The PI3K/AKT/mTOR signaling pathway has an important role in NPC, promoting cell proliferation and inhibiting apoptosis [28]. In recent studies, many mechanisms of silencing the PI3K/AKT/mTOR signaling pathway by traditional Chinese medicine have been reported to be related to anticancer effects [29, 30]. We found that the activation of the PI3K/AKT/mTOR signaling pathway by IGF-1 reversed the effect of euscaphic acid on proliferation, the cell cycle, and apoptosis. These results showed that euscaphic acid regulated the PI3K/AKT/mTOR signaling pathway to exert anticancer effects in NPC cells.

In summary, we demonstrated the euscaphic acid inhibits the proliferation and promotes apoptosis in NPC cells through the silencing of the PI3K/AKT/mTOR signaling pathway. We believed that euscaphic acid has the potential for development as an anticancer drug for NPC. However, before euscaphic acid can be developed as an anticancer agent, its antitumor activity should be investigated *in vivo* and in clinical settings.

Acknowledgements

The study was granted by research funding project of Guangdong Provincial Administration of traditional Chinese Medicine (NO. 2011-0178).

Disclosure of conflict of interest

None.

Address correspondence to: Quanxi Mei, Pharmacology Laboratory, Zhongshan Hospital, Guangzhou University of Chinese Medicine, No.3, Kang Xin Road, West District, Zhongshan 528401, Republic of China. Tel: +86-13802668925; E-mail: quanxi-mei@126.com

References

- [1] Parkin DM and Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992; 45-173.
- [2] Nielsen NH, Mikkelsen F and Hansen JP. Nasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo population. Acta Pathol Microbiol Scand A 1977; 85: 850-858.
- [3] Teo P, Yu P, Lee WY, Leung SF, Kwan WH, Yu KH, Choi P and Johnson PJ. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996; 36: 291-304.
- [4] Chambers MS, Garden AS, Kies MS and Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004; 26: 796-807.
- [5] McMillan AS, Pow EH, Leung WK, Wong MC and Kwong DL. Oral health-related quality of life in southern Chinese following radiotherapy for nasopharyngeal carcinoma. J Oral Rehabil 2004; 31: 600-608.
- [6] Devi PU. Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Indian J Exp Biol 1996; 34: 927-932.
- [7] Han MQ, Liu JX and Gao H. Effects of 24 Chinese medicinal herbs on nucleic acid, protein and cell cycle of human lung adenocarcinoma cell. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995; 15: 147-149.
- [8] Lee KH. Novel antitumor agents from higher plants. Med Res Rev 1999; 19: 569-596.
- [9] Spaulding-Albright N. A review of some herbal and related products commonly used in cancer patients. J Am Diet Assoc 1997; 97: S208-215.
- [10] Zhang P, Zhao SR, Liu F, Sun XJ and Liu H. Oridonin induces apoptosis in human nasopharyngeal carcinoma cells involving ROS generation. Folia Biol (Praha) 2017; 63: 155-163.
- [11] Lin HF, Hsieh MJ, Hsi YT, Lo YS, Chuang YC, Chen MK and Chien SY. Celastrol-induced apoptosis in human nasopharyngeal carcinoma is associated with the activation of the death receptor and the mitochondrial pathway. Oncol Lett 2017; 14: 1683-1690.
- [12] Qi G, Chen J, Shi C, Wang Y, Mi S, Shao W, Yu X, Ma Y, Ling J and Huang J. Cinnamic Acid (CINN) induces apoptosis and proliferation in human nasopharyngeal carcinoma cells. Cell Physiol Biochem 2016; 40: 589-596.
- [13] Martini S, D'Addario C, Colacevich A, Focardi S, Borghini F, Santucci A, Figura N and Rossi C. Antimicrobial activity against Helicobacter py-

Euscaphic acid inhibits the progression of nasopharyngeal carcinoma

- lori strains and antioxidant properties of blackberry leaves (*Rubus ulmifolius*) and isolated compounds. *Int J Antimicrob Agents* 2009; 34: 50-59.
- [14] Thiem B and Goslinska O. Antimicrobial activity of *Rubus chamaemorus* leaves. *Fitoterapia* 2004; 75: 93-95.
- [15] Choi J, Lee KT, Ha J, Yun SY, Ko CD, Jung HJ and Park HJ. Antinociceptive and antiinflammatory effects of Niga-ichigoside F1 and 23-hydroxytormentonic acid obtained from *Rubus coreanus*. *Biol Pharm Bull* 2003; 26: 1436-1441.
- [16] Lee JH, Ham YA, Choi SH, Im EO, Jung JH, Im KS, Kim DK, Xu Y, Wang MW and Kim ND. Activity of crude extract of *Rubus crataegifolius* roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor. *Arch Pharm Res* 2000; 23: 338-343.
- [17] Zheng ZX, Zhang LJ, Huang CX, Huang QL, Wei XD, Wu XY and Zhou WM. Antitumour effect of total saponins of *Rubus parvifolius* on malignant melanoma. *Zhongguo Zhong Yao Za Zhi* 2007; 32: 2055-2058.
- [18] Badr AM, El-Demerdash E, Khalifa AE, Ghoneim AI, Ayoub NA and Abdel-Naim AB. *Rubus sanctus* protects against carbon tetrachloride-induced toxicity in rat isolated hepatocytes: isolation and characterization of its galloylated flavonoids. *J Pharm Pharmacol* 2009; 61: 1511-1520.
- [19] Hong ZF, Li TJ and Zhao JY. Effect of total alkaloids of *Rubus alceaefolius* poiron on gene expressions of CYP2E1 and CYP3A1 in rats with acute liver injury. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2009; 29: 711-715.
- [20] Mei Q, Sun X, Gao Y and Zhou X. Research progress on prevention and treatment of nasopharyngeal carcinoma with traditional Chinese medicine. *China Pharmaceuticals* 2007; 28-29.
- [21] Murakami C, Ishijima K, Hirota M, Sakaguchi K, Yoshida H and Mizushina Y. Novel anti-inflammatory compounds from *Rubus sieboldii*, triterpenoids, are inhibitors of mammalian DNA polymerases. *Biochim Biophys Acta* 2002; 1596: 193-200.
- [22] Vivanco I and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer* 2002; 2: 489-501.
- [23] Yang N, Qu YJ, Cheng Y, Liang T, Zhang MN, Zhang D, Dong LN, Wang XW and Zhang GM. Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway. *Cancer Biomark* 2017; 19: 263-269.
- [24] Zhong JT, Yu J, Wang HJ, Shi Y, Zhao TS, He BX, Qiao B and Feng ZW. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. *Tumour Biol* 2017; 39: 1010428317697562.
- [25] Banno N, Akihisa T, Tokuda H, Yasukawa K, Taguchi Y, Akazawa H, Ukiya M, Kimura Y, Suzuki T and Nishino H. Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of *Eriobotrya japonica*. *Biol Pharm Bull* 2005; 28: 1995-1999.
- [26] Kim YK, Yoon SK and Ryu SY. Cytotoxic triterpenes from stem bark of *Physocarpus intermedium*. *Planta Med* 2000; 66: 485-486.
- [27] Rocha Gda G, Simoes M, Lucio KA, Oliveira RR, Coelho Kaplan MA and Gattass CR. Natural triterpenoids from *Cecropia lyratiloba* are cytotoxic to both sensitive and multidrug resistant leukemia cell lines. *Bioorg Med Chem* 2007; 15: 7355-7360.
- [28] Lin YT, Wang HC, Chuang HC, Hsu YC, Yang MY and Chien CY. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. *J Mol Med (Berl)* 2018; 96: 1407-1418.
- [29] Yanwei L, Yinli Y and Pan Z. Traditional herbal formula NPC01 exerts antiangiogenic effects through inhibiting the PI3K/Akt/mTOR signaling pathway in nasopharyngeal carcinoma cells. *Evid Based Complement Alternat Med* 2018; 2018: 5291517.
- [30] Lin YT, Wang HC, Hsu YC, Cho CL, Yang MY and Chien CY. Capsaicin induces autophagy and apoptosis in human nasopharyngeal carcinoma cells by downregulating the PI3K/AKT/mTOR pathway. *Int J Mol Sci* 2017; 18.